Status | Study |
Active, not recruiting |
Study Name: Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Condition: Neuromyelitis Optica Neuromyelitis Optica Date: 2014-10-21 Interventions: Drug: Ublituximab Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which |
Active, not recruiting |
Study Name: Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Condition: Devic's Syndrome Devic's Neuromyelitis Op Date: 2014-09-15 Interventions: Biological: Autologous mesenchymal stem cells Autologous mesenchymal stem cells |
Recruiting |
Study Name: A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Condition: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders (NMO/NMOSD) Date: 2014-07-16 Interventions: Biological: MEDI-551 Other: Placebo |
Recruiting |
Study Name: Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Condition: Neuromyelitis Optica Date: 2014-03-11 Interventions: Drug: Alpha1-antitrypsin Other |
Enrolling by invitation |
Study Name: An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Condition: Neuromyelitis Optica Neuromyelitis Optica Date: 2013-11-18 Interventions: Biological: eculizumab Other Name: Soliris |
Active, not recruiting |
Study Name: Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Condition: Neuromyelitis Optica Neuromyelitis Optica Date: 2013-09-03 Interventions: Drug: Mitoxantrone The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 month |
Recruiting |
Study Name: A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Condition: Neuromyelitis Optica Neuromyelitis Optica Date: 2013-06-20 Interventions: Drug: Eculizumab Induction Phase: 900 mg IV weekly X 4 Mai |
Completed |
Study Name: Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Condition: Neuromyelitis Optica Spectrum Disorder Date: 2013-04-26 Interventions: Drug: NPB-01 Other Name: Intravenous immunoglobulin |
Completed |
Study Name: Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Condition: Neuromyelitis Optica Neuromyelitis Optica Date: 2013-01-21 Interventions: Drug: Bevacizumab Other Name: Avastin |
Completed |
Study Name: C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Condition: Neuromyelitis Optica Date: 2012-12-29 Interventions: Drug: C1-esterase inhibitor (Cinryze) Other Name: Cinryze |